Metabolic & Fat Optimization
Retatrutide — the next-generation triple agonist for fat loss research.
Retatrutide is Lilly's investigational triple agonist of GLP-1, GIP and glucagon receptors. Phase 2 data showed up to 24% body-weight reduction at 48 weeks — outperforming semaglutide and tirzepatide.
Each PeptidePen is filled in a controlled cleanroom and sealed with tamper-evident packaging. Batch documentation includes identity confirmation, HPLC purity analysis and concentration verification. Strictly for in-vitro research — not for human or veterinary use.
A full breakdown of mechanism, clinical findings, dosing references and safety signals — for researchers who want the complete picture.
Retatrutide is a peptide that simultaneously activates three receptors: GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and glucagon receptors. This multi-receptor targeting approach offers a highly effective way to study complex metabolic conditions such as type 2 diabetes, obesity, and related cardiovascular diseases.
Unlike traditional peptide agonists that act on only one receptor, Retatrutide engages three distinct metabolic pathways, delivering enhanced efficacy and better tolerability in research models. It has a prolonged duration of action that supports convenient once-weekly dosing, making it an ideal compound for research in metabolic diseases and regenerative medicine.
Besides metabolic and obesity research, Retatrutide is also being studied for its potential in reducing inflammation, improving lipid profiles, and preventing cardiovascular complications.
Designed to significantly improve blood sugar regulation, promote fat loss, and enhance overall metabolic markers, Retatrutide's triple receptor mechanism opens up unique opportunities for medical research.
Retatrutide works by activating three key metabolic receptors — GLP-1, GIP, and glucagon — resulting in combined effects that improve blood sugar control, suppress appetite, and promote fat loss.
• GLP-1 receptors: Stimulation boosts insulin secretion, helping reduce blood glucose levels. It also slows gastric emptying, extending feelings of fullness and lowering calorie intake, while suppressing glucagon — a hormone that raises liver glucose production.
• GIP receptors: Activation complements GLP-1 by enhancing insulin response and improving peripheral insulin sensitivity. GIP activity also reduces inflammation and supports better lipid metabolism by lowering triglycerides and LDL cholesterol.
• Glucagon receptors: Promote fat breakdown (lipolysis) and thermogenesis, aiding in fat tissue reduction. This effect is especially useful for obesity research and energy balance regulation.
Retatrutide has undergone extensive preclinical and clinical evaluation, demonstrating safety and effectiveness in metabolic disorder models. Ongoing clinical trials, including phase 2 studies, are further investigating its impact on obesity, type 2 diabetes, lipid metabolism, and inflammation.
Clinical trials have tested Retatrutide's ability to influence metabolic disease markers. Researchers continue to explore its long-term effects on blood sugar regulation, weight reduction, and cardiovascular protection.
Phase 2 trials have shown notable weight reduction and improved blood sugar control. Participants experienced lasting reductions in body fat, enhanced insulin sensitivity, and better lipid metabolism — with up to ~24% body-weight reduction at 48 weeks.
• Type 2 Diabetes: Studies indicate Retatrutide significantly lowers HbA1c (glycated hemoglobin) levels, improving long-term glucose management. Its triple receptor action offers superior glycemic control compared to single-target GLP-1 agonists.
• Weight Loss: In obese cohorts, Retatrutide promotes substantial fat reduction by suppressing appetite, increasing thermogenesis (heat production to burn fat), and stimulating fat breakdown. These mechanisms make it a potent agent for weight management research.
Retatrutide has been shown to improve lipid profiles by lowering triglycerides and LDL cholesterol while increasing HDL (good cholesterol), thereby reducing cardiovascular risk markers. It also exhibits anti-inflammatory effects, which may benefit studies on chronic inflammation, metabolic syndrome, and autoimmune disease.
Retatrutide is a multi-receptor peptide agonist engineered to target GLP-1, GIP, and glucagon receptors efficiently. Its stabilized helical structure enhances receptor binding and extends its biological half-life, reducing the frequency of administration. This unique structure supports its metabolic effects — increased lipolysis, appetite regulation, and glucose balance — making it valuable for obesity and metabolic disorder research.
Developed as part of a new wave of multi-target peptide therapies, Retatrutide aims to surpass the limitations of single-receptor agonists by combining triple receptor activation. Clinical and preclinical studies have demonstrated its superior efficacy and prolonged action, with ongoing research exploring broader therapeutic applications in metabolic and cardiovascular conditions.
• Blood Sugar Control: Enhances insulin secretion, sensitivity, and reduces glucagon — driving excellent glucose regulation in type 2 diabetes research.
• Weight Loss: Suppresses appetite and promotes fat breakdown, making it effective in obesity studies.
• Cardiovascular Protection: Improves lipid profiles and reduces inflammation, lowering cardiovascular risk markers.
• Metabolic Research: A useful tool for investigating energy balance, lipid metabolism, and metabolic syndrome mechanisms.
• Chronic Disease Potential: May offer benefits in chronic inflammatory and neurodegenerative disease models.
• Quality of Life Markers: Supports increased energy, less fatigue, and overall improvement through metabolic control.
Retatrutide is generally well tolerated in studies, but some mild to moderate side effects may occur — often early in titration — including:
• Gastrointestinal symptoms (nausea, vomiting, diarrhea, constipation)
• Headaches
• Mild heart rate increase
• Application site reactions (redness, itching, swelling)
• Fatigue or weakness
These effects are usually temporary. Severe or persistent symptoms should be addressed with a healthcare professional.
Both peptides are advanced metabolic compounds, but Retatrutide activates three receptors (GLP-1, GIP, glucagon) while Tirzepatide targets only two (GLP-1, GIP). This triple receptor action may provide enhanced fat metabolism, thermogenesis, and energy regulation, positioning Retatrutide as a promising option for obesity and metabolic research. Studies continue to clarify the distinct benefits of each peptide in glucose control and cardiovascular health.
This compound is intended strictly for in-vitro observation and research-related purposes. The information presented is based on a range of scientific studies and analyses but is not intended to diagnose, treat, or prevent any medical conditions.
Triple incretin/glucagon receptor activation
Up to ~24% weight reduction in trials
Improves glycemic control and lipid profile
Energy expenditure boost via glucagon arm
Weekly subcutaneous research dosing, titrated from low microgram range.
For in-vitro research design reference only.
Form
Pre-mixed pen
Purity
≥99% HPLC
Storage
2–8°C
Shipping
Cold-chain
COA
Batch-matched
Select pen size and shipping region at checkout.
Each batch is HPLC-assayed and documented.
Insulated, temperature-logged delivery.
Reference dosing and references included.
Common questions about Retatrutide (Standard Pen) and PeptidePen orders.
No. All PeptidePen products are strictly for in-vitro laboratory research. Not intended for human or veterinary use.
Each pen ships with a batch-matched certificate of analysis. A digital copy is also available on request via your order confirmation.
Orders ship cold-chain (2–8°C) with insulated packaging, ice packs and a temperature log. Tracked delivery in the US and EU.
Yes. Contact our team for institutional pricing, custom concentrations and recurring shipments.
Damaged or off-spec pens are replaced free of charge. Contact support within 7 days of delivery.
Pre-mixed, batch-assayed, cold-chain shipped — order before 2pm for same-day dispatch.
